Find the right patients,
faster.

At a critical moment in our Phase 2 trial analysis, Qairnel team’s responsiveness and deep understanding of our data were invaluable. It was always a pleasure to engage in thoughtful, efficient discussions on how to get the best out of our data and results.

Recruitment remains the biggest hurdle in drug development. Qairnel’s screening platform is exactly the kind of solution we need to identify the right patients early — directly from the general population. Paired with their expertise in data and neuroscience, they’re the ideal partner to help development move faster and smarter

Working with Qairnel allowed us to identify fast progressors in our Phase 2 trial by generating a digital twin for each participant at baseline. We showed that the same outcome could have been achieved with 10% fewer participants — a significant gain in efficiency.

To truly understand patients — their needs, preferences, and early signs of change — we need real-world data collected directly in their everyday lives. That’s exactly what Qairnel enables for people living with neurocognitive disorders and their caregivers.